Skip to content
IP + Technology Law
Home  »  News & Insights  »  Presentation

Knobbe Martens Webinar Series: Strategic Considerations in Patent Subject Matter Eligibility Under Section 101 – Revised Guidance Examples

November 19, 2020  | Mauricio Uribe and Dan Altman

EU Webinar_page_Banner_1_0.png

Partners Mauricio Uribe and Dan Altman presented a Webinar focused on strategic considerations for patent prosecution in the United States in view of the statutory requirements of Section 101.

View live presentation: Video Link

Knobbe Martens on Vimeo

View and download the full presentation below.
Knobbe Martens Webinar Series: Strategic Considerations in Patent Subject Matter Eligibility Under Section 101 – Revised Guidance Examples

Knobbe Martens Webinar Series: Strategic Considerations in Patent Subject Matter Eligibility Under Section 101 from Knobbe Martens – Intellectual Property Law
Knobbe Martens Webinar Series: Strategic Considerations in Patent Subject Matter Eligibility Under Section 101 – Revised Guidance Examples Headshot

Dan Altman
Partner
Orange County
dan.altman@knobbe.com
949-760-0404

Related Links

Practice Areas

News & Insights

Blog - Section 101
Nov 2025
The USPTO’s Evolving Approach to Patent Eligibility: Insights from Director Squires’ AIPLA Address
On October 31, 2025, Director Squires spoke to the American Intellectual Property Law Association and provided a forceful statement on his view for the direction of patent law. Of particular...
Publications
Oct 2025
USPTO Proposes Rule and Director Implements Policy Likely to Limit Multiple Patent Validity Challenges
On Friday, October 17, the USPTO published a proposed rule that, if implemented, would likely reduce filings of inter partes review patent validity challenges. In addition, USPTO Director John Squires...
News
Oct 2025
Knobbe Martens Secures Federal Circuit Win for Edwards Lifesciences in Prosthetic Heart Valve Patent Dispute
IRVINE, Calif., October 29, 2025 –  Knobbe Martens is pleased to announce the firm has obtained a significant appellate victory for Edwards Lifesciences in a high-stakes patent infringement dispute involving...